Details for Patent: 9,745,290
✉ Email this page to a colleague
Which drugs does patent 9,745,290 protect, and when does it expire?
Patent 9,745,290 protects ONGENTYS and is included in one NDA.
This patent has thirty-one patent family members in twenty-three countries.
Summary for Patent: 9,745,290
| Title: | Dosage regimen for COMT inhibitors |
| Abstract: | The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. |
| Inventor(s): | Learmonth; David Alexander (Valongo, PT), Kiss; Laszlo Erno (Lavra, PT), Palma; Pedro Nuno Leal (Leca da Palmeira, PT), Ferreira; Humberto dos Santos (S. Mamede do Coronado, PT), Soares da Silva; Patricio Manuel V. A. (Porto, PT) |
| Assignee: | BIAL--PORTELA & CA, S.A. (Sao Mamede do Coronado, PT) |
| Application Number: | 14/689,397 |
|
Patent Claim Types: see list of patent claims | Use; Compound; Dosage form; |
Recent additions to Drugs Protected by US Patent 9,745,290
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE | 212489 | Apr 24, 2020 | RX | Yes | ⤷ Try a Trial | Y | ⤷ Try a Trial | U-3869 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 9,745,290
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-002 | Apr 24, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,745,290
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 07002091 | Jan 31, 2007 | |
International Family Members for US Patent 9,745,290
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 065098 | ⤷ Try a Trial | |||
| Argentina | 109590 | ⤷ Try a Trial | |||
| Australia | 2007346018 | ⤷ Try a Trial | |||
| Brazil | PI0721213 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
